

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

GRANT OF SHARE AWARDS PURSUANT TO 2026 SHARE AWARD SCHEME

This announcement is made by Meilleure Health International Industry Group Limited (the “**Company**”), pursuant to Rules 17.06A, 17.06B and 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

References are made to the circular of the Company (the “**Circular**”) dated 27 March 2026 and the announcement of the Company dated 21 April 2026 in relation to the 2026 Share Award Scheme. Unless otherwise defined, terms used in this announcement shall have the same meanings as ascribed to them in the Circular.

The Board announces that on 03 July 2026, the Company granted an aggregate of 5,328,000 Awarded Shares, representing approximately 0.13% of the total number of Shares in issue as at the date of this announcement, to 3 employees of the Company and its subsidiaries (the “**Grantees**”) pursuant to the terms of the 2026 Share Award Scheme at nil consideration, subject to the acceptance by each of the Grantees, as incentives for their continuing and/or future contributions to the Company and its subsidiaries.

GRANT OF AWARD SHARES

Details of the grant of Awarded Shares (the “**Award Grant**”) are as follows:

Date of grant	: 03 July 2026
Number of Grantees	: 3 employees of the Company and its subsidiaries
Number of Award Grant	: 5,328,000 Awarded Shares, representing approximately 0.13% of the total number of Shares in issue as at the date of this announcement. The 5,328,000 Awarded Shares shall be the Treasury Shares held by the Company.
Purchase price of the Awards Shares granted	: Nil consideration. No amount is payable by Grantees in the 2026 Share Award Scheme upon the application for or acceptance of a grant of Awarded Shares.
Closing price of the Shares on the date of grant	: HK\$0.249 per Share
Vesting period of the Share Awards	: One year from the date of grant.
Performance targets of the Shares Awards	: There are no performance targets attached to the Awarded Shares granted. The Remuneration Committee of the Company considers that the value of the Awarded Shares is linked to the future market value of the Company, and granting the Awarded Shares to the Grantees unconditionally is sufficient to achieve the purpose of the 2026 Share Award Scheme to align their interests with those of the Company and its shareholders, therefore no performance targets are necessary.
Clawback mechanism	: There is no additional clawback mechanism attached to the Awarded Shares granted other than the existing terms provided in the 2026 Share Award Scheme. The Remuneration Committee considers that the lapse and cancellation mechanisms under specific circumstances already covered in the terms of the 2026 Share Award Scheme are sufficient to protect the Company's interests, thus no additional clawback mechanism is necessary.

The Award Grant, once vested, is not subject to any clawback mechanism.

The Award Grant is not subject to approval by the Shareholders. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, each of the Grantees is not (i) a Director, nor a chief executive, or a substantial shareholder, or an associate of any of them; (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; (iii) a related entity participant or service provider with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the total issued Shares (excluding treasury shares).

REASONS FOR AND BENEFITS OF THE GRANT OF THE SHARE AWARDS

The purpose of the 2026 Share Award Scheme is to recognise the contributions or the future contributions by certain employees and persons to the Group, to provide them with incentives in order to retain them for the continuous operation and development of the Group, and to attract suitable personnel for further development of the Group. The grant of Share Awards to the Grantees is designed to recognise their significant contribution of the Grantees to the Company's operational success and strategic development in the past. The Company has elected to settle part of such performance-linked remuneration in the form of equity rather than cash, which enables the Company to maintain prudent cash flow management while at the same time aligning the interests of the Grantees more closely with those of the Shareholders. The Board believes that the Award Grant will further motivate the employees' ongoing dedication, enhance employee engagement and align their interests with those of the Shareholders in a competitive talent market.

SHARES AVAILABLE FOR FUTURE GRANT UNDER THE 2026 SHARE AWARD SCHEME

The aggregate number of Shares underlying all grants made pursuant to the 2026 Share Award Scheme shall not exceed 408,842,863 Shares. As at the date of this announcement, 403,514,863 Shares will remain available for future grants under the 2026 Share Award Scheme.

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 03 July 2026

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Professor Chau Chi Wai, Wilton, Mr. Chen Shi and Mr. Wu Peng as independent non-executive Directors.